Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Phys Med Biol ; 65(24): 245044, 2020 12 22.
Article in English | MEDLINE | ID: mdl-33181493

ABSTRACT

Magnetic field correction factors are needed for absolute dosimetry in magnetic resonance (MR)-linacs. Currently experimental data for magnetic field correction factors, especially for small volume ionization chambers, are largely lacking. The purpose of this work is to establish, independent methods for the experimental determination of magnetic field correction factors [Formula: see text] in an orientation in which the ionization chamber is parallel to the magnetic field. The aim is to confirm previous experiments on the determination of Farmer type ionization chamber correction factors and to gather information about the usability of small-volume ionization chambers for absolute dosimetry in MR-linacs. The first approach to determine [Formula: see text] is based on a cross-calibration of measurements using a conventional linac with an electromagnet and an MR-linac. The absolute influence of the magnetic field in perpendicular orientation is quantified with the help of the conventional linac and the electromagnet. The correction factors for the parallel orientation are then derived by combining these measurements with relative measurements in the MR-linac. The second technique utilizes alanine electron paramagnetic resonance dosimetry. The alanine system as well as several ionization chambers were directly calibrated with the German primary standard for absorbed dose to water. Magnetic field correction factors for the ionization chambers were determined by a cross-calibration with the alanine in an MR-linac. Important quantities like [Formula: see text] for Farmer type ionization chambers in parallel orientation and the change of the dose to water due the magnetic field [Formula: see text] have been confirmed. In addition, magnetic field correction factors have been determined for small volume ionization chambers in parallel orientation. The electromagnet-based measurements of [Formula: see text] for [Formula: see text] MR-linacs and parallel ionization chamber orientations resulted in 0.9926(22), 0.9935(31) and 0.9841(27) for the PTW 30013, the PTW 31010 and the PTW 31021, respectively. The measurements based on the second technique resulted in values for [Formula: see text] of 0.9901(72), 0.9955(72), and 0.9885(71). Both methods show excellent accuracy and reproducibility and are therefore suitable for the determination of magnetic field correction factors. Small-volume ionization chambers showed a variation in the resulting values for [Formula: see text] and should be cross-calibrated instead of using tabulated values for correction factors.


Subject(s)
Magnetic Fields , Radiometry/instrumentation , Calibration , Particle Accelerators , Reproducibility of Results , Water
2.
Endocrine ; 59(1): 39-49, 2018 01.
Article in English | MEDLINE | ID: mdl-29030774

ABSTRACT

PURPOSE: In adults, growth hormone deficiency (GHD) has been associated with low bone mineral density (BMD), an effect counteracted by growth hormone (GH) replacement. Whether GH is beneficial in adults with age-related bone loss and without hypopituitarism is unclear. METHODS: We conducted a systematic literature search using Medline, Embase and the Cochrane Register of Controlled Trials. We extracted and analyzed data according to the bone outcome included [bone mineral content (BMC), BMD, and bone biomarker, fracture risk]. We performed a meta-analysis when possible. RESULTS: We included eight studies. Seven randomized 272 post-menopausal women, 61-69 years, to GH or control, for 6-24 months, and the eighth was an extension trial. Except for one study, all women received concurrent osteoporosis therapies. There was no significant effect of GH, as compared to control, on BMD at the lumbar spine (Weighted mean difference WMD = -0.01 [-0.04, 0.02]), total hip (WMD = 0 [-0.05, 0.06]) or femoral neck (WMD = 0 [-0.03, 0.04]). Similarly, no effect was seen on BMC. GH significantly increased the bone formation marker procollagen type-I carboxy-terminal propeptide (PICP) (WMD = 14.03 [2.68, 25.38]). GH resulted in a trend for increase in osteocalcin and in bone resorption markers. Patients who received GH had a significant decrease in fracture risk as compared to control (RR = 0.63 [0.46, 0.87]). Reported adverse events were not major, mostly related to fluid retention. CONCLUSION: GH may not improve bone density in women with age-related bone loss but may decrease fracture risk. Larger studies of longer duration are needed to further explore these findings in both genders, and to investigate the effect of GH on bone quality.


Subject(s)
Bone Density/drug effects , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Hypopituitarism/drug therapy , Osteoporosis/drug therapy , Osteoporotic Fractures/prevention & control , Aged , Female , Fractures, Bone/epidemiology , Fractures, Bone/prevention & control , Hormone Replacement Therapy , Humans , Hypopituitarism/complications , Middle Aged , Osteoporosis/complications , Osteoporosis/epidemiology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/etiology , Randomized Controlled Trials as Topic/statistics & numerical data , Risk Factors
3.
Radiother Oncol ; 120(2): 346-8, 2016 08.
Article in English | MEDLINE | ID: mdl-27267047

ABSTRACT

Multi-criteria optimization provides decision makers with a range of clinical choices through Pareto plans that can be explored during real time navigation and then converted into deliverable plans. Our study shows that dosimetric differences can arise between the two steps, which could compromise the clinical choices made during navigation.


Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Prostatic Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted/methods , Humans , Male , Radiometry , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/standards , Radiotherapy, Intensity-Modulated , Retrospective Studies
4.
Z Med Phys ; 26(4): 362-370, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27156924

ABSTRACT

PURPOSE: To provide high-quality and efficient dosimetric planning for various types of stereotactic body radiotherapy (SBRT) for tumor treatment using a multicriteria optimization (MCO) technique fine-tuned with direct machine parameter optimization (DMPO). METHODS AND MATERIALS: Eighteen patients with lung (n=11), liver (n=5) or adrenal cell cancer (n=2) were treated using SBRT in our clinic between December 2014 and June 2015. Plans were generated using the RayStation™ Treatment Planning System (TPS) with the VMAT technique. Optimal deliverable SBRT plans were first generated using an MCO algorithm to find a well-balanced tradeoff between tumor control and normal tissue sparing in an efficient treatment planning time. Then, the deliverable plan was post-processed using the MCO solution as the starting point for the DMPO algorithm to improve the dose gradient around the planning target volume (PTV) while maintaining the clinician's priorities. The dosimetric quality of the plans was evaluated using dose-volume histogram (DVH) parameters, which account for target coverage and the sparing of healthy tissue, as well as the CI100 and CI50 conformity indexes. RESULTS: Using a combination of the MCO and DMPO algorithms showed that the treatment plans were clinically optimal and conformed to all organ risk dose volume constraints reported in the literature, with a computation time of approximately one hour. The coverage of the PTV (D99% and D95%) and sparing of organs at risk (OAR) were similar between the MCO and MCO+DMPO plans, with no significant differences (p>0.05) for all the SBRT plans. The average CI100 and CI50 values using MCO+DMPO were significantly better than those with MCO alone (p<0.05). CONCLUSIONS: The MCO technique allows for convergence on an optimal solution for SBRT within an efficient planning time. The combination of the MCO and DMPO techniques yields a better dose gradient, especially for lung tumors.


Subject(s)
Algorithms , Decision Support Systems, Clinical , Neoplasms/radiotherapy , Organ Sparing Treatments/methods , Radiosurgery/methods , Radiotherapy Planning, Computer-Assisted/methods , Humans , Organs at Risk/radiation effects , Radiation Protection/methods , Radiotherapy Dosage , Reproducibility of Results , Sensitivity and Specificity
5.
Med Phys ; 43(1): 205, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26745913

ABSTRACT

PURPOSE: Flattening filter free (FFF) beams generated by medical linear accelerators are today clinically used for stereotactical and non-stereotactical radiotherapy treatments. Such beams differ from the standard flattened beams (FF) in the high dose rate and the profile shape peaked on the beam central axis. Definition of new parameters as unflatness and slope for FFF beams has been proposed based on a renormalization factor for FFF profiles. The present study aims to assess the dosimetric differences between FFF beams generated by linear accelerators from different vendors, and to provide renormalization and parameter data of the two kinds of units. METHODS: Dosimetric data from two Varian TrueBeam and two Elekta Versa HD linear accelerators, all with 6 and 10 MV nominal accelerating potentials, FF and FFF modes have been collected. Renormalization factors and related fit parameters according to Fogliata et al. ["Definition of parameters for quality assurance of flattening filter free (FFF) photon beams in radiation therapy," Med. Phys. 39, 6455-6464 (2012)] have been evaluated for FFF beams of both units and energies. Unflatness and slope parameters from profile curves were evaluated. Dosimetric differences in terms of beam penetration and near-the-surface dose were also assessed. RESULTS: FFF profile parameters have been updated; renormalization factors and unflatness from the Varian units are consistent with the published data. Elekta FFF beam qualities, different from the Varian generated beams, tend to express similar behaviour as the FF beam of the corresponding nominal energy. TPR20,10 for 6 and 10 MV FF and FFF TrueBeam beams are 0.665, 0.629 (6 MV) and 0.738, 0.703 (10 MV). The same figures for Versa HD units are 0.684, 0.678 (6 MV) and 0.734, 0.721 (10 MV). CONCLUSIONS: Renormalization factor and unflatness parameters evaluated from Varian and Elekta FFF beams are provided, in particular renormalization factors table and fit parameters.


Subject(s)
Radiotherapy, Computer-Assisted/methods , Engineering , Particle Accelerators , Quality Control , Radiometry , Radiotherapy Dosage , Radiotherapy, Computer-Assisted/instrumentation
6.
J Appl Clin Med Phys ; 16(3): 5410, 2015 May 08.
Article in English | MEDLINE | ID: mdl-26103500

ABSTRACT

The purpose of this work is to evaluate the volumetric-modulated arc therapy (VMAT) multicriteria optimization (MCO) algorithm clinically available in the RayStation treatment planning system (TPS) and its ability to reduce treatment planning time while providing high dosimetric plan quality. Nine patients with localized prostate cancer who were previously treated with 78 Gy in 39 fractions using VMAT plans and rayArc system based on the direct machine parameter optimization (DMPO) algorithm were selected and replanned using the VMAT-MCO system. First, the dosimetric quality of the plans was evaluated using multiple conformity metrics that account for target coverage and sparing of healthy tissue, used in our departmental clinical protocols. The conformity and homogeneity index, number of monitor units, and treatment planning time for both modalities were assessed. Next, the effects of the technical plan parameters, such as constraint leaf motion CLM (cm/°) and maximum arc delivery time T (s), on the accuracy of delivered dose were evaluated using quality assurance passing rates (QAs) measured using the Delta4 phantom from ScandiDos. For the dosimetric plan's quality analysis, the results show that the VMAT-MCO system provides plans comparable to the rayArc system with no statistical difference for V95% (p < 0.01), D1% (p < 0.01), CI (p < 0.01), and HI (p < 0.01) of the PTV, bladder (p < 0.01), and rectum (p < 0.01) constraints, except for the femoral heads and healthy tissues, for which a dose reduction was observed using MCO compared with rayArc (p < 0.01). The technical parameter study showed that a combination of CLM equal to 0.5 cm/degree and a maximum delivery time of 72 s allowed the accurate delivery of the VMAT-MCO plan on the Elekta Versa HD linear accelerator. Planning evaluation and dosimetric measurements showed that VMAT-MCO can be used clinically with the advantage of enhanced planning process efficiency by reducing the treatment planning time without impairing dosimetric quality.


Subject(s)
Algorithms , Organ Sparing Treatments/methods , Prostatic Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted/methods , Radiotherapy, Intensity-Modulated/methods , Humans , Male , Organs at Risk/radiation effects , Radiotherapy Dosage , Treatment Outcome
7.
Prim Care Diabetes ; 9(3): 168-71, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25466161

ABSTRACT

Antimicrobial therapy is well known to be associated with fluctuations of blood glucose levels. This review aims at exploring the association between glycemic fluctuations and antibiotics mainly focusing on quinolones. Quinolones are associated with hypoglycemia and hyperglycemia. Several mechanism are proposed to explain this causality.


Subject(s)
Anti-Bacterial Agents/adverse effects , Blood Glucose/drug effects , Hyperglycemia/chemically induced , Hypoglycemia/chemically induced , Quinolones/adverse effects , Animals , Biomarkers/blood , Blood Glucose/metabolism , Humans , Hyperglycemia/blood , Hyperglycemia/diagnosis , Hypoglycemia/blood , Hypoglycemia/diagnosis , Risk Assessment , Risk Factors
8.
Curr Diabetes Rev ; 10(6): 360-3, 2014.
Article in English | MEDLINE | ID: mdl-25316147

ABSTRACT

Corticosteroid-induced hyperglycemia is a common medical problem which can cause frequent hospitalizations and therefore relates to an increase in morbidity. Metformin, sulfonylureas, thiazolidinediones and insulin are well known available therapies for the treatment of steroid induced hyperglycemia. Incretin based therapies are a newly developing strategies with a considerable importance in the treatment regimen as well. This review aims at discussing the pathophysiology of steroid induced hyperglycemia in addition to the available therapies used for treatment, focusing on incretin therapies.


Subject(s)
Adrenal Cortex Hormones/adverse effects , Diabetes Mellitus, Type 2/prevention & control , Hyperglycemia/chemically induced , Incretins/therapeutic use , Blood Glucose , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/chemically induced , Dose-Response Relationship, Drug , Hospitalization , Humans , Hyperglycemia/blood , Hypoglycemic Agents/therapeutic use , Incretins/blood , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...